Beyond the Purity Headline: Contaminant Screening Questions for a Small UK Biotech Bench

ByAndrei Petrescu

A certificate of analysis lands in the shared drive, the figure at the top reads ≥99%, and the batch is signed into the freezer. On a busy bench, that is often where the scrutiny stops. For a small UK biotech team — a handful of researchers, one or two cell lines, a purchasing budget that will not stretch to a full quality department — the habit is understandable. It is also the point at which avoidable variables creep into an experiment. Headline purity is one number produced by one method. Contaminant screening is the broader question: what else was tested for, by which technique, on which material, and how would you demonstrate all of that eighteen months later when a reviewer or an auditor asks?

What a Headline Purity Figure Actually Covers — and What It Leaves Open

Most peptide purity figures come from reverse-phase high-performance liquid chromatography (HPLC) and are reported as percentage peak area at a defined wavelength. That definition matters. Detection at around 214 nm responds to the peptide backbone, but any species without a suitable chromophore — salts, residual solvents, water, certain counterions — is effectively invisible to the detector. Two compounds with similar hydrophobicity may also co-elute under a given gradient. A statement of ≥99% therefore means, precisely, that 99% of the detectable peak area under those conditions sat in the main peak. It is a useful indicator of synthetic clean-up, not a complete description of what is in the vial.

Identity is a separate question with a separate test. A single, symmetrical peak tells you the material is chromatographically uniform; it does not confirm the sequence. Mass spectrometry, amino acid analysis or sequencing approaches are what close that gap. The shop states that every compound includes a CoA covering purity and identity by HPLC, and the homepage lists CoAs Janoshik Analytical Reports. Both are published claims that should be reconfirmed against the actual batch document rather than taken from a category page or a marketing banner.

Then there is the contaminant layer that purity testing never reaches. Heavy metals are typically assessed by ICP-MS; bacterial endotoxin by limulus-based methods; residual trifluoroacetate, solvents and water content need their own assays. The supplier’s own About page describes an expanded testing framework — heavy metals and endotoxin screening alongside CoA documentation — as a later milestone in its development. That is the shop’s published wording, not an independently audited certification, and researchers should confirm on the live site and on the batch CoA which tests were actually performed.

Why should an in-vitro bench care about metals and endotoxin at all? Because both interfere with assays. Trace metal ions can inhibit enzymes, quench fluorescence and shift redox-sensitive readouts. Endotoxin engages TLR4 signalling in mammalian cell work and can distort cytokine and reporter data even when the peptide itself is behaving perfectly. Screening is not only a compliance ritual; it is a variable-control measure for cell-based and biochemical work.

Questions Worth Putting to a Supplier Before You Accept a Batch

A short, consistent set of questions, asked every time and filed with the batch record, does more for a small team than an elaborate vendor scorecard. The aim is not to interrogate the supplier but to establish exactly what the document in front of you proves.

Ask which tests ran, on which material

The critical distinction is between testing performed on the delivered lot and testing performed on a reference sample. Restocked products may carry the same Internal Test Reference (ITR) as earlier stock; the ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or that they have been independently tested in their own right. If your work is sensitive to lot-to-lot variation, ask the question directly and record the answer.

Ask how the document connects to your vial

Vial labels use a reference format that combines the SKU code with an expiry date, for example BPC10-03/27, and that reference links to the corresponding CoA. Quote it whenever you contact the shop about documentation. Two further points are worth internalising: vial cap colour is not an indicator of identity, analytical quality or manufacturing origin, and all peptides contain trace amounts of mannitol, an excipient used for lyophilisation behaviour, solubility and storage protection. That excipient matters when you calculate concentration by mass, because the vial contents are not purely peptide.

The supplier also states that it does not supply blended peptides, recommending instead that individual vials be combined only within a controlled experimental design. From a screening standpoint that is helpful: one vial, one CoA, one traceable set of test results per component. Researchers reviewing the current catalogue — where you can Buy peptides and then open the batch CoA for each item — should treat that document as the starting point for a conversation, not the end of one. If a heavy-metal or endotoxin result is quoted, check which sample it belongs to and when it was generated.

Turning Documentation Into a Bench Workflow

Good screening practice is mostly record-keeping discipline. On receipt, log the SKU, vial reference, CoA version, ITR where quoted, and the month and year of receipt, then hold the material in quarantine until the paperwork matches the delivery. Inspect the lyophilised cake visually and note any abnormality before the vial enters general stock. These steps take minutes and save hours during a troubleshooting cycle.

Handling should stay strictly within an in-vitro laboratory workflow. Allow vials to reach ambient temperature before opening, work in a clean environment, and remove only the quantity required for the experiment. Where reconstitution is needed, record the diluent, the volume added and the resulting concentration for the assay in question; the reconstitution calculator published on the site is for laboratory research use only and must never be used for human or veterinary dosing. All materials supplied are research-use-only and are not for human or veterinary use, consumption or clinical application.

Storage follows the same logic. Lyophilised peptides should be held at −20°C or below, sealed with desiccant and protected from moisture, heat and light; reconstituted material is less stable and should be kept at 2–8°C for short-term laboratory use, with repeated freeze–thaw cycles avoided. The shop describes temperature-aware storage and tracked UK dispatch, and its published delivery timing is an estimate rather than a guarantee, so plan around it. Purchasers remain responsible for lawful use, safe handling, storage, disposal and COSHH compliance.

Consider how this plays out in practice. A bench running a reporter assay notices a change in signal-to-noise after a new lot enters circulation. The productive first move is to open the batch record: was endotoxin screening documented for that lot, what reconstitution volume was used, was the diluent lot logged, how many freeze–thaw cycles has the vial seen? Working through those variables in order isolates the cause far faster than replacing reagents at random. Whatever the outcome, the CoA, the vial reference and the handling notes belong together in the same file — because the number at the top of the certificate is only ever as useful as the tests behind it.

Related Posts:

Similar Posts